Janssen awarded breakthrough therapy designation for Genmab bone marrow cancer drug

The US authorities see potential for a groundbreaking treatment in talquetamab, which is being developed by Janssen based on Genmab’s technology.

Photo: PR / Genmab

Drug candidate talquetamab could potentially significantly improve treatment options for people with recurring or treatment-resistant bone marrow cancer, the FDA has concluded.

It has therefore awarded the candidate a breakthrough therapy designation, a special status which is granted to candidates where study data suggests a breakthrough is being made in treatment, and special attention should be paid by the authorities.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs